Objective: To provide a comprehensive overview of bempedoic acid and ezetimibe combination therapy, including its mechanism of action, recent evidence on its benefits and safety, and future potential as a new cardioprotective therapy, particularly in high CVD risk patients.
Methodology: Literature search was performed on 3 search engines: PubMed/MEDLINE, ScienceDirect, and Cochrane Library. The included studies were assessed for the quality of study methods and reported data. Data were synthesized narratively, summarizing and discussing various research findings of combination therapy.
Conclusion: Bempedoic acid and ezetimibe combination therapy had a potential advantage in reducing CVD risk. Several simulation studies predicted that the cardioprotective effects of bempedoic acid and ezetimibe FDC therapy would advance the monotherapies.
Key words: Bempedoic acid, ezetimibe, LDL-cholesterol, hypercholesterolemia, cardiovascular diseases.
|
Download PDF 
Post
